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Abstract
Background: Sexually active young people attending London further education (FE) colleges have high rates of
chlamydia, but screening rates are low. We will conduct a cluster randomised feasibility trial of frequent, rapid, on-
site chlamydia testing and same-day treatment (Test and Treat (TnT)) in six FE colleges (with parallel qualitative and
economic assessments) to assess the feasibility of conducting a future trial to investigate if TnT reduces chlamydia
rates.
Methods: We will recruit 80 sexually active students aged 16–24 years from public areas at each of six colleges. All
participants (total n = 480) will be asked to provide samples (urine for males, self-taken vaginal swabs for females)
and complete questionnaires on sexual lifestyle and healthcare use at baseline and after 7 months. Participants will
be informed that baseline samples will not be tested for 7 months and be advised to get screened separately.
Colleges will be randomly allocated to the intervention (TnT) or the control group (no TnT).
One and 4 months after recruitment, participants at each intervention college (n = 3) will be texted and invited for
on-site chlamydia tests using the 90-min Cepheid GeneXpert system. Students with positive results will be asked to
see a visiting nurse health adviser for same-day treatment and partner notification, (backed by genitourinary
medicine follow-up). Participants in control colleges (n = 3) will receive ‘thank you’ texts 1 and 4 months after
recruitment.
Seven months after recruitment, participants from both groups will be invited to complete questionnaires and
provide samples for TnT. All samples will be tested, and same-day treatment offered to students with positive
results.
Acceptability of TnT will be assessed by qualitative interviews of purposively sampled students (n = 30) and
college staff (n = 12). We will collect data on costs of TnT and usual healthcare.
(Continued on next page)
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Discussion: Findings will provide key values to inform feasibility, sample size and timescales of a future definitive
trial of TnT in FE colleges, including:
 Recruitment rates
 TnT uptake rates
 Follow-up rates
 Prevalence of chlamydia in participants at baseline and 7 months
 Acceptability of TnT to students and college staff
 Estimate of the cost per person screened/treated in TnT versus usual care
Trial registration: International Standard Randomised Controlled Trials Registry, ID: ISRCTN58038795, Registered on
31 August 2016.
Keywords: Rapid chlamydia tests, Screening, Young people, Further education colleges, Test and treat, Cluster
randomised, Feasibility trial
Background
There are high rates of sexually transmitted infections
(STIs) in ethnically diverse, sexually active students aged
16–24 years attending London further education (FE) col-
leges [1–4], with around 8% testing positive for Chlamydia
trachomatis. However, uptake of chlamydia screening re-
mains low: below 30% annually in 16–24-year-olds in Eng-
land [4, 5]. Although chlamydia primarily affects young
people, the consequences of infection such as infertility,
chronic pelvic pain or epididymitis can last a lifetime. It is
estimated that 10–16% of women with untreated chlamydia
will develop clinical pelvic inflammatory disease of whom
8% will have an ectopic pregnancy and 11% will suffer from
tubal-factor infertility [6]. The cost of chlamydia to the
NHS is estimated to be over £100 million each year.
Barriers to reducing chlamydia rates include low up-
take of testing by those most at risk [5, 7] (such as sexu-
ally active teenagers, people from ethnic minorities and
people who are socioeconomically deprived), and long
delays in receiving a positive diagnosis or attending for
treatment. Introducing rapid, on-the-spot chlamydia
tests and treatment into the community could make it
easier for young people to get tested and treated faster,
and before they can pass on their infection. It might also
prevent complications [8, 9]. These novel tests can have
99% sensitivity and 99.4% specificity [10], and studies
have demonstrated their feasibility in remote communi-
ties [11]. However, there have been no UK trials of rapid
STI tests and same-day, on-site treatment (Test and
Treat (TnT)) in non-healthcare settings.
We will use a test that checks for gonorrhoea as well
as chlamydia as this would likely be included in a
real-life roll out. However, as people diagnosed with
gonorrhoea are best managed by a sexual health clinic
they will not receive on-site treatment. Hence, TnT will
be just for chlamydia.
Our cluster randomised feasibility trial aims:
1. To assess the feasibility of conducting a trial of TnT
in FE colleges, and obtain estimates of key values to
inform sample size estimates and timescales for a
definitive trial
2. To explore the acceptability of TnT through a
qualitative evaluation
3. To estimate the cost per person tested and treated
in TnT versus usual care
Design
Cluster randomised controlled feasibility trial over 7
months with parallel qualitative and economic assess-
ments (Fig. 1 and Additional file 1: Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) 2013 Checklist (Fig. 2)). The outcome is within
one academic year to optimise follow-up.
Setting
Six ethnically diverse FE colleges in London FE colleges
take students from the age of 16 years and teach both
academic subjects and vocational courses such as
plumbing and hairdressing. As previously [3] we will
first obtain agreement from staff and student bodies.
Participants
At each site during 2 days, 80 consecutive sexually active
students (total 480 students across all sites) aged 16–
24 years will be recruited. We previously found that
such students are a high-risk group: 43% report two or
more sexual partners in the past year, 34% smoke ciga-
rettes, 50% are teenagers and 30% are from black ethnic
minority groups [3].
Exclusion criteria
Students who have never had penetrative sexual inter-
course; students with severe learning disability.
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Fig. 1 Shows the design of the Test n Treat (TnT) cluster randomised feasibility trial
STUDY PERIOD
Enrolment Allocation Post-allocation
Follow up 
at 7 
months
TIMEPOINT** -t1 0 Month 1 TnT Month 4 TnT tx
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS:
[TnT test n treat @ 
1 and 4 months]
ASSESSMENTS:
Provide 
genitourinary 
samples
x x
Questionnaire
x X
*Recommended content can be displayed using various schematic formats. See SPIRIT 2013
Explanation and Elaboration for examples from protocols.
**List specific timepoints in this row.
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure showing the schedule of enrolment, interventions, and
assessments for the Test n Treat (TnT) chlamydia screening feasibility trial
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Recruitment and consent (September to October 2016)
Research assistants will approach students in common
room areas [3, 12]. The students will be asked if they are
willing to help with research on sexual health. Students
aged 16–24 will be invited to come to the study table
where recruiters will explain that as the study is about
chlamydia and sexually transmitted infections, only stu-
dents who have had penetrative sexual intercourse
should consider taking part. Those who are interested
will be given a patient information sheet and consent
form to read and be encouraged to ask questions.
The information sheet will explain that participants
will be asked to complete short confidential electronic
questionnaires on sexual health using a tablet computer,
and to provide samples on this day and again after
7 months (urine for males and self-taken vaginal swabs
for females). In half the colleges, students will also be
asked to provide samples for rapid testing for chlamydia
and gonorrhoea after 1 and 4 months, and those found
to be infected with chlamydia will be given same-day,
on-site treatment. Some students may also be invited to
take part in interviews [13].
Research assistants will ensure that all participants under-
stand that samples provided at recruitment will not be
tested for 7 months and it is the student’s responsibility to
get tested separately [3] (e.g. at a sexual health clinic or at a
general practice) if they are allocated to the control group
or if they want to be tested for other STIs such as HIV.
These stored baseline samples are for three reasons:
1. To emulate the processes of a future definitive trial
2. To ensure that all participants know how simple it
is to provide samples for testing
3. To measure baseline chlamydia prevalence at each
site in order to refine the intra-class correlation
coefficient (ICC) for sample size calculations
Students who agree to take part will be asked to sign a
consent form and to provide full contact details includ-
ing mobile number and email for follow-up and text re-
minders [3]. They will be asked for consent to obtain
their NHS numbers and to allow the researchers to ac-
cess their GP, hospital, and genitourinary medicine
(GUM) clinic records [14].
Honoraria for participants
Honoraria will be provided both to facilitate recruitment
[15, 16] and to encourage participants to return repeat
samples at the end of the trial. (We have ethical approval
for honoraria and have shown them to be very effective
[16]). Participants will be given £5 when they return
completed sample packs at recruitment, and £10 at the
final 7-month follow-up. Participants in the qualitative
interviews will be given £10 for their time. However,
participants in intervention colleges will not be given
honoraria to attend for TnT after 1 and 4 months as this
would not happen were the intervention to be rolled out
in future.
Data collection at baseline (September to October 2016)
During recruitment, participants will be asked to
complete a confidential baseline questionnaire using a
tablet computer. Questions will include date of birth,
self-assigned ethnicity, smoking, alcohol, age at sexual
debut, condom use, contraception, number of sexual
partners in the previous 12 months, when they last had
sex with a new partner, recent STI testing and treatment,
history of STI, and genitourinary symptoms in the past 6
months [3]. All participants will also be asked to provide
samples in the nearest toilet.
Randomisation
Randomisation will take place once recruitment is com-
pleted and baseline data collected for all colleges.
Using a computer programme, colleges will be ran-
domly allocated into the intervention (TnT) or the con-
trol (no TnT) by the trial statisticians RP and FR. The
randomisation will be constrained to ensure that three
colleges are allocated to each group.
Intervention TnT colleges – rapid chlamydia/gonorrhoea
testing and same-day chlamydia treatment (1 and 4
months after recruitment)
In November 2016, 1 month after recruitment, each
intervention campus will be visited on two consecutive
days by the TnT team. These will be the same days of
the week as at recruitment to optimise student attend-
ance. The 80 participating students in each campus will
be texted and invited to come for on-site rapid chla-
mydia/gonorrhoea testing and same-day treatment for
chlamydia. As at recruitment they will be invited to
complete a questionnaire and provide a sample, but this
time the sample will be tested immediately on site using
the Cepheid GeneXpert system which takes 90 min. Par-
ticipants will be given a card containing information
about the local GUM/sexual health clinic, a link to the
Brook sexual health website: https://www.brook.org.uk,
and TnT study contact details.
Negative results will be texted. Participants with posi-
tive results will be telephoned by the nurse health ad-
viser and invited to see her in the college nurse’s room
for confidential same-day treatment if positive for chla-
mydia, partner notification, advice, and follow-up. In-
fected students will be asked to bring any sexual
partners who attend the college so they can also be
tested and treated. (In a survey in 2014, 9% of 103 stu-
dents said they had a sexual partner at the same FE col-
lege.) Students who are positive for gonorrhoea will be
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asked to attend St George’s NHS Trust GUM clinic for
further testing and review by a clinician.
All participants in the three intervention colleges will
be invited to provide repeat samples for on-site TnT 4
months after recruitment (i.e. the next term January–
February 2017).
Control ‘usual care’ colleges (1 and 4 months after
recruitment)
Participants from the three control colleges will not get
TnT but will receive texts 1 and 4 months after recruit-
ment thanking them for being in the study.
Data collection at 7-month follow-up (April–May 2017)
All participants will be asked to provide samples for
TnT and to complete questionnaires at college at 7
months. Follow-up questionnaires will include additional
questions about STI testing and treatment, oral sex, vac-
cination against human papillomavirus (HPV), and use
of healthcare services for sexual health since recruitment
date, including attendances at general practice, sexual
health or hospital clinics, hospital admissions, and drug
treatment [3, 17].
When we invite them to the outcome assessment we will
send participants a link to an additional consent form and
information sheet explaining that we will be asking them to
provide optional mouthwash samples (for future testing for
HPV and chlamydia/gonorrhoea) as well as genitourinary
samples. We will also put this information on the study
webpage. For those who attend we will provide paper cop-
ies of the additional consent form and information sheet
and answer any questions. We will explain that providing
the mouthwash sample is optional and for research pur-
poses only and, that as chlamydia/gonorrhoea and HPV
tests are not validated on these samples, we will not feed-
back results. Those who agree will be asked to sign the add-
itional consent form.
Testing at 7 months is required in the proposed full trial
in order to calculate the main outcome (prevalence of chla-
mydia), and is included here to test the feasibility of collect-
ing these data. It will also help inform estimates of effect
size for sample size calculations. Treatment of those diag-
nosed with infection at 7 months will also be offered. This
is not part of the assessed intervention, but is offered to en-
hance testing uptake at this time, and participation in gen-
eral among the control group. In addition, at the end of the
study stored baseline samples will be tested using standard
tests, and students with positive results will be contacted by
the health adviser [3].
Masking
Recruitment of colleges and participants will be con-
ducted prior to group allocation3,19. Therefore, the base-
line data collection from students will be blind to
treatment group. By the time of the first TnT interven-
tion 1 month after baseline, participants and research as-
sistants will no longer be blinded.
Qualitative evaluation exploring the acceptability of TnT
A research assistant will conduct semi-structured inter-
views [13] with a purposive sample of male and female
college staff and students to investigate views on the ac-
ceptability of TnT including barriers and facilitators to
uptake and possible harms.
1. College staff (n = 12)
We will interview teaching and student welfare staff
and explore opinions of the acceptability of the interven-
tion, barriers, facilitators, harms, and challenges to
reaching certain subgroups such as male teenagers from
ethnic minorities. We will also explore views on the trial
methodology and suggested improvements.
2. Students (n = 30)
These interviews will explore opinions on acceptabil-
ity, barriers, and facilitators to uptake of TnT, and views
of potential harms of on-site rapid tests and treatment.
We will also seek views as to the trial methodology and
suggested improvements.
Interviews will focus on three distinct groups:
1. Students who declined to participate in the trial
(n = 10) who agree to be interviewed to explore
factors influencing their decision
2. Participants (n = 10) in intervention sites who used
TnT
3. Participants (n = 10) in intervention sites who were
recruited but did not use TnT
Interviews will be digitally recorded with permission,
transcribed and thematically analysed.
Health economic analysis
We will estimate the cost per person screened and
treated of implementing TnT in FE colleges compared
with usual care (no TnT), and the incremental cost per
chlamydia infection averted. Costs will be classified as
solely research; capital set-up costs; or on-going running
costs. We will also assess the feasibility of obtaining
questionnaire data on healthcare use during the study
period. Based on what participants report in their
7-month questionnaires about healthcare setting
attended for chlamydia-related problems, we will explore
the feasibility of estimating the health resources used in
both arms of the study using published tariff costs for
GUM, hospital inpatient and outpatient visits, and GP
attendance [17]. We will explore the marginal costs of
offering TnT at 1 and 4 months compared to no test.
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Results will inform the cost of implementing TnT in a
definitive trial.
Main outcomes
1. Key values to inform feasibility, sample size, and
timescales of a full trial of TnT in FE colleges:
(a) Recruitment rates:
 Recruitment rate: colleges and students
 Time taken to recruit 80 participants at each
site
 Age, gender, and ethnicity of students
recruited versus not recruited [16]
(b) Testing and treatment uptake rates
(1 and 4 months after recruitment):
 Testing and treatment uptake rates, in
intervention sites only
 Time from provision of sample to treatment
of chlamydia positives
(c) Follow-up rates (at 7 months):
 Percentage providing samples at all sites
 Percentage completing final questionnaires
(including data on healthcare usage)
(d) Prevalence of chlamydia in participants at each
site at baseline and at 7 months. Chlamydia
prevalence at baseline will enable us to refine
the ICC, and prevalence at 7 months to refine
the estimated effect size, both required for
sample size calculations for the substantive trial
2. A perspective on the acceptability of TnT in FE
colleges, emerging from qualitative interviews with
purposively sampled students and college staff
3. Health economic analysis (as described above)
Estimate of the cost per person screened/treated in
TnT versus usual care.
Sample size and statistical analysis
Assuming a 30% recruitment rate [12], 1600 students
will be approached to recruit 480 overall (80 per site
across six sites, three intervention, and three control).
Estimates of testing uptake at 1 and 4 months (interven-
tion sites only) will be based on 240 students, and at
7 months will be based on 480 students (all sites).
Teare et al. [18] recommend that 60 to 100 subjects is
sufficient to estimate an event rate with acceptable pre-
cision in a feasibility study. Prevalence of chlamydia at
baseline will be estimated separately for each of the six
sites (80 students per site), and these prevalences will be
used to inform the intraclass correlation coefficient
(ICC), required for the sample size calculation for the
main study. From our previous research involving 11
colleges [3], the ICC was estimated to be 0.005 (95%
confidence interval (CI) − 0.013 to 0.026). Adding data
from another six colleges will improve the precision of
this ICC, reducing the width of the confidence interval
by around 20%.
Assuming 70% followed up at 7 months (with £10
honoraria), final estimates of chlamydia prevalence
would be based on 168 students in each of the interven-
tion and control groups. The study is not powered to
find a statistically significant difference, but this may
provide useful information on possible effect size to in-
form future sample size calculations.
Statistical analysis
Summary of baseline data and flow of patients
A Consolidated Standards of Reporting Trials (CONSORT)
flow diagram will be produced to show the number of stu-
dents recruited, the numbers attending at 7-month final
follow-up, and for those not attending the reasons (where
available) for non-attendance including lost-to-follow-up
and withdrawal. Baseline descriptions of students recruited
to the study will be presented by treatment arm: including
means and standard deviation or numbers and proportions
as appropriate. This will be repeated to compare the base-
line characteristics of those in the intervention arm return-
ing for TnT at 1 and 4 months compared to those who did
not return. Where available reasons for non-attendance at
the 1- and 4-month visits will be summarised. Summary
characteristics of participants at the FE colleges will also be
summarised by treatment arm. No statistical significance
testing will be performed.
Main outcomes analysis
Recruitment rates (colleges and students) will be calcu-
lated as proportions with corresponding 95% CIs. This
will include the proportion of colleges participating in
the study of the total number of colleges asked to par-
ticipate, and, where available, the proportion of students
who were eligible of the total number of students who
were assessed for eligibility. The proportion of students
tested, who obtain a positive test result and receive treat-
ment, will be calculated at 1 and 4 months for the inter-
vention group and at 7 months for both the intervention
and the control groups, and corresponding 95% CIs will
be presented.
The time taken to recruit students will be summarised
by means and standard deviations or medians and
inter-quartile ranges as appropriate, for each site and
overall. At intervention colleges we will summarise the
time from providing a sample to treatment for students
with a positive chlamydia test at 1 and 4 months with
means and standard deviations or medians and
inter-quartile ranges as appropriate. All confidence inter-
vals will be two-sided and will be at the 95% level. A de-
tailed statistical analysis plan has been developed and
approved by the Trial Steering Committee [19].
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Discussion
To our knowledge this will be the first UK cluster rando-
mised study exploring the feasibility of rapid chlamydia
tests and same-day, on-site treatment in the community. If
the findings lead to a main trial which shows that TnT is
acceptable, cost-effective and reduces chlamydia rates,
implementing TnT in the community might improve the
sexual health of many hard-to-reach young people.
Trial status
We are recruiting participants.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents. (DOC 121 kb)
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